360 completed, 48 recruiting, 45 unknown, 35 terminated. 548 Phase 2, 78 Phase 1, 64 Phase 3.
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Novel Approaches to Supporting Students With ADHD in Multi-Tiered Systems of Support Academic Competency Enhancement (ACE) classroom, School as Usual Classroom Supports - Attention Deficit Hyerpactivity Disorder | Phase 2 / Phase 3 | Not yet recruiting | Florida International University | 544 | 2027-01-01 | 2026-09-28 |
| Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism Ganaxolone (Ztalmy), Placebo - Autism in Children, Autistic Disorder in Children and Adolescents | Phase 2 | Not yet recruiting | Stanford University | 66 | 2027-01-01 | 2026-06-09 |
| A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD) | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 120 | 2026-12-01 | 2026-10-09 |
| Role of Omega-DEK in Childhood Apraxia of Speech Omega-DEK, L-carnitine, Placebo - Childhood Apraxia of Speech, Verbal Apraxia | Phase 2 | Not yet recruiting | Claudia R. Morris | 34 | 2026-11-01 | 2026-07-29 |
| Heart Rate Variability Biofeedback for Anxiety in Autistic Youth Lief Smart Patch - Autism Spectrum Disorder, Anxiety | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2026-10-26 | 2026-10-16 |
| Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders ILT-101 ld-(IL2), NaCl (0,9%) - Autism Spectrum Disorder | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 22 | 2026-10-01 | 2026-05-15 |
| TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS PPF3, Placebo - Autism Disorder | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 100 | 2026-10-01 | 2026-10-29 |
| Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations Everolimus blinded oral capsules, Placebo - Cowden's Disease, Cowden's Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Boston Children's Hospital | 60 | 2026-09-01 | 2026-06-04 |
| A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD Fecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID - ADHD, ADHD - Attention Deficit Disorder With Hyperactivity | Phase 2 | Not yet recruiting | University of Calgary | 64 | 2026-08-31 | 2026-09-10 |
| A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) ALKS 7290, Placebo - Attention Deficit Disorder With Hyperactivity (ADHD) | Phase 2 | Recruiting | Alkermes, Inc. | 312 | 2026-08-10 | 2026-10-29 |
| A Placebo-controlled Trial of Folinic Acid in Children With ASD Folinic Acid, Placebo - Autism Spectrum Disorder | Phase 2 | Recruiting | Prof. Adi Aran | 150 | 2026-06-23 | 2026-06-22 |
| SCI-110 in the Treatment of Tourette Syndrome SCI-110, Placebo - Tourette Syndrome | Phase 2 | Not yet recruiting | Neurothera Labs Inc. | 164 | 2026-06-01 | 2026-04-21 |
| Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome CTH120, CTH120 placebo hard capsules - Fragile X Syndrome (FXS), Fragile X Syndrome | Phase 2 | Recruiting | Connecta Therapeutics, S.L. | 30 | 2026-05-21 | 2026-07-17 |
| Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) Experimental: Full-spectrum CBG oil 30 mg/mL, Placebo oil (MCT oil) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 60 | 2026-05-01 | 2026-05-18 |
| Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders. Cannabidiol - Neurodevelopmental Disorders With Severe Self-injuries | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 21 | 2026-05-01 | 2026-05-04 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial Xylitol Chewing gum, Sorbitol chewing gum - Preterm Birth, Low Birthweight Neonate | Phase 2 / Phase 3 | Recruiting | University of Washington | 6000 | 2026-03-26 | 2026-09-10 |
| Xenon Therapy for Children With Autism Spectrum Disorder Xenon - Autism Spectrum Disorder (ASD), Autism | Phase 1 / Phase 2 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 72 | 2026-03-01 | 2026-02-27 |
| Enhancing Orthographic Communication and Literacy Outcomes for AAC Learners ALLSTAR - Literacy, Communication, Nonverbal | Phase 1 / Phase 2 | Not yet recruiting | Penn State University | 60 | 2026-03-01 | 2026-02-03 |
Showing 20 of 548. Sign in to see all of them.
Autism Spectrum Disorder (179) · Attention Deficit Disorder with Hyperactivity (175) · Autistic Disorder (161) · Tourette Syndrome (45) · Child Development Disorders, Pervasive (22) · Anxiety Disorders (20) · Asperger Syndrome (20) · Intellectual Disability (17) · Fragile X Syndrome (13) · Learning Disabilities (11) · Conduct Disorder (10) · Mental Disorders (10) · Depression (9) · Spasm (9)
Mental Disorders (538) · Child Development Disorders, Pervasive (249) · Attention Deficit and Disruptive Behavior Disorders (179) · Nervous System Diseases (129) · Autism Spectrum Disorder (91) · Pathological Conditions, Signs and Symptoms (89) · Signs and Symptoms (86) · Neurologic Manifestations (85) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (81) · Genetic Diseases, Inborn (77) · Heredodegenerative Disorders, Nervous System (70) · Central Nervous System Diseases (60) · Neurobehavioral Manifestations (60) · Brain Diseases (57)
Methylphenidate (28) · Atomoxetine Hydrochloride (19) · Oxytocin (14) · Therapeutics (10) · Acetylcysteine (9) · Leucovorin (9) · Sodium Chloride (8) · Cognitive Behavioral Therapy (7) · Lisdexamfetamine Dimesylate (7) · pozanicline (7) · valbenazine (7) · Amphetamine (6) · Aripiprazole (6) · Cannabidiol (6) · Fatty Acids, Omega-3 (6)
Stanford University (18) · Holland Bloorview Kids Rehabilitation Hospital (10) · Massachusetts General Hospital (10) · National Institute of Mental Health (NIMH) (10) · New York State Psychiatric Institute (9) · Neurocrine Biosciences (7) · University of California, Los Angeles (7) · University of California, San Francisco (7) · Arizona State University (6) · Assistance Publique - Hôpitaux de Paris (6) · Eli Lilly and Company (6) · Shire (6) · AbbVie (prior sponsor, Abbott) (5) · Boston Children's Hospital (5) · Forest Laboratories (5)
United States (355) · Canada (43) · France (22) · Israel (22) · Germany (16) · Spain (16) · China (13) · Australia (11) · Italy (9) · Japan (9) · Poland (9) · United Kingdom (8) · Brazil (7) · Norway (7) · Taiwan (7)
Evdokia Anagnostou, M.D. (8) · Linmarie Sikich, MD (7) · Alexander Kolevzon, MD (5) · Antonio Hardan, MD (4) · Antonio Y. Hardan, MD (4) · Craig Surman, MD (4) · James McCracken, MD (4) · Richard E Frye, MD, PhD (4) · Frances R Levin, M.D. (3) · James B Adams, PhD (3)
PMID 37811711, PMID 36006807, PMID 20732631, PMID 21156272, PMID 24001701, PMID 24144615, PMID 25988365, PMID 26763495, PMID 28202705, PMID 29029679, PMID 37460385, PMID 38114596, PMID 38363467, PMID 10341379, PMID 10385840, PMID 10917410, PMID 11514638, PMID 11918106, PMID 12849360, PMID 14605787, PMID 14662594, PMID 14733976, PMID 15026214, PMID 15212606, PMID 15328899, PMID 16041867, PMID 16102908, PMID 16481664, PMID 16540816, PMID 16890481, PMID 17109795, PMID 17284136, PMID 17352947, PMID 17520797, PMID 17631866, PMID 17671050, PMID 18315448, PMID 18469236, PMID 18544723, PMID 18555170, PMID 18632997, PMID 19148734, PMID 19186083, PMID 19309326, PMID 19398354, PMID 19487623, PMID 19491110, PMID 19849639, PMID 19877974, PMID 20048226
2025 (4), 2019 (3), P50HD109861 (3), 2018 (2), K99HD101702 (2), R01DC017476 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2017 (1), 5KL2TR001109-05 (1), F31MH096375 (1), K23NS055733 (1), K24AA000301 (1)